Skip to Content

News & Events

Show:

Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new...

READ MORE

Crinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new...

READ MORE

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Crinetics announces the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price...

READ MORE

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics announces that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of...

READ MORE

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics announces the submission of a New Drug Application to the FDA for its investigational drug, paltusotine, for the treatment...

READ MORE

2024 Cantor Global Healthcare Conference

Event Date: September 18, 2024

READ MORE

Crinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new...

READ MORE

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Crinetics management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global...

READ MORE